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Aim: To perform a systematic review of the literature on the concurrent validity, predictive validity and
responsiveness of radiographic metric measurement of femoro-acetabular joint space width (JSW) in hip
osteoarthritis (OA).
Methods: Eligibility criteria: studies reporting any data on (1) JSW on X-rays in hip OA patients and (2)
concurrent validity (correlations with clinical symptoms), predictive validity (correlations with future
symptomatic state, joint space loss or joint replacement), and/or responsiveness (JSW change over time
evaluated using the standardized response mean (SRM)). Search strategy: Medline PUBMED and Embase
databases. Statistical analysis: Random-effects models were constructed to obtain pooled SRMs.
Results: Of 448 articles, 79 met the abstract inclusion criteria and were read for further screening. Of
these, 15 reported measures of validity and 11 reported measures of responsiveness. Concurrent validity:
Five studies suggested an association between JSW and symptoms in the general population. Two
evaluated the correlations between JSW and symptoms in hip OA patients, with conﬂicting results. Five
demonstrated that JSW is predictive of future hip joint replacement. Responsiveness was moderate
(SRM¼ 0.66; 95% conﬁdential interval (95%CI): 0.41, 0.91), but tended to be lower in randomized clinical
trials than in cohort studies (0.35 vs 0.83), using an intention to treat rather than a completer analysis
(0.30 vs 0.80), and using manual rather than computer-based measurement (0.47 vs 1.12).
Conclusion: There is evidence of a weak association between JSW and symptoms, of predictive validity for
subsequent joint replacement, and of moderate responsiveness of metric measurement of JSW.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Osteoarthritis (OA) is a major cause of disability worldwide. For
many years, there has been a major interest among the scientiﬁc
community, pharmaceutical companies, and regulatory agencies in
the development of drugs that might inﬂuence the natural history
of OA by preventing, retarding, or reversing cartilage breakdown.
These disease-modifying OA drugs (DMOADs) need to be evaluated
in trials using outcomes measures that reﬂect the natural history of
OA. Radiographic variables, particularly metric measurement of
minimal joint space width (JSW), are considered the mostJ.F. Maillefert, Department of
000 Dijon, France. Tel: 33-3-
fr (J.F. Maillefert).
s Research Society International. Pappropriate structural outcome measure1. However, the clinical
relevance of this outcome remains doubtful, since there is a debate
onwhether an associationwith clinical symptoms exists. Moreover,
the responsiveness is questionable since the progression of disease
is frequently slow and variable from one patient to another.
Recently, international working groups were created under the
auspices of the Food and Drug Administration (FDA) and the
Osteoarthritis Research Society International (OARSI) in order to
revisit and discuss the outcomes used in OA trials; one of these
groups examined the assessment of structural change (ASC). The
members of this group agreed that the ﬁrst stage of their work was
to assess the current knowledge on the properties of the instru-
ments used to evaluate structural variables in OA. To assess
a potential outcome measure, it is necessary to assess its psycho-
metric properties, as deﬁned by the Outcome Measures inublished by Elsevier Ltd. All rights reserved.
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ﬁlter checks that a potential outcome measure is truthful, reliable,
and sensitive to change over time and between different severity
stages. This report presents a systematic analysis of the literature
performed on the concurrent validity, predictive validity and
responsiveness of radiographic metric measurement of hip JSW in
hip OA.
Methods
The draft strategy for the literature review was written in
December 2008, sent to all members of the ASC working group,
underwent iterative revision, and a ﬁnal version of the protocol was
approved in February 2009. The protocol is available and can be
obtained from the corresponding author of the present article.
Eligibility criteria
Studies were eligible for analysis when reporting data on hip OA
patients (regardless of the deﬁnition employed) and including
1 metric measurement of the hip joint JSW on X-rays, irre-
spective of the measurement technique (manually or
computer-based method, evaluation of minimal, mean joint
space, or joint area), the study design (cross-sectional or
longitudinal), the presence of an intervention or not, or the
presence of controls
2 concurrent validity of JSW (correlations with clinical symp-
toms, in particular pain and function) and/or predictive validity
(correlation with future symptoms, joint space loss, or joint
replacement), and/or responsiveness (JSW change over time)
using either the reported standardized response mean (SRM)
or where data allowing calculation of the SRM was available.Publications excluded on the 
basis of the abstract: N=369 
79 publications 
Publications excluded after 
obtaining the full text: N=54 
- Data unavailable for both validity 
and sensitivity to change = 10 
- Data on responsiveness but not 
hip OA patients = 10 
- JSW not reported or evaluated 
using an atlas = 18 
- Duplicate = 8 
- Review or editorial or not original 
data = 7 
- Data on responsiveness available 
but not in a control group = 1 
24 publications: 
- 13 for validity 
- 9 for sensitivity to change 
- 2 for both 
Fig. 1. Flow-chart of the screening process for articles included in the systematic
review.Search strategy
A systematic search of the literature was performed in March
2009 and updated in July 2009, using theMedline PUBMED and the
Embase databases. The following search terms were used: ((Oste-
oarthritis[MeSH]) and (hip)) AND (X-ray OR radiography OR diag-
nostic imaging OR radiology OR disease progression) AND (joint
space OR JSW OR disease progression). We limited the search to
research conducted in humans and published in English, French,
German or Spanish languages.
A quality control of the search terms was performed in January
2009: 30 relevant articles were selected at random from one
investigator’s personal library. All were found to include the search
terms. In addition, a manual search of the references of all screened
full-text articles was performed. The abstracts of all potential
relevant citations referenced were also screened.
Screening and extraction
All abstracts were read by one reviewer (JFM). Full-text articles
were obtained if likely to be relevant or where relevance could not
be determined from the abstract.
Criteria for exclusion were: studies reporting results on OA
joints other than hip, or combined results on hip and other joint OA
which did not present hip results separately, no radiographic
evaluation or radiographic data not reported, radiographic assess-
ment not evaluated by metric measurement of JSW (thus excluding
studies in which joint space was evaluated using an atlas),
secondary OA, and case reports. Reviews, editorials, comments, and
systematic literature reviews were not included.A full-text review of the articles was performed by one reviewer
(DCML) using a predetermined data abstraction form approved by
the ASC group. The data extracted included the year of publication,
name of the ﬁrst author, study design, X-ray acquisition and
measurement technique, evaluated population or patients, demo-
graphics, baseline and when available follow-up clinical status
(pain, function), baseline and when available follow-up JSWmetric
measurement, change in JSW (mean and standard deviation), SRM,
cross-sectional and longitudinal relationship between JSW metric
measurement and clinical status, relationship between JSW and
further joint space loss and/or total joint replacement.
After data extraction, a second reviewer (JFM) read all the arti-
cles to ensure quality control of data extraction.
Statistical analysis
Responsiveness was assessed by the SRM, deﬁned as the mean
change in minimum JSW divided by the standard deviation of
change. Articles reporting the SRM or its components were
included in the analysis. For randomized clinical trials (RCTs), only
the placebo arm was entered to ensure a measure of the natural
D. Chu Miow Lin et al. / Osteoarthritis and Cartilage 19 (2011) 543e549 545history of disease progression. Pooled estimates of the SRM were
performed using random-effects models. We calculated the overall
pooled SRM along with the pooled SRM by study design (cohort vs
RCT), analysis type (intention to treat (ITT) vs completers), and
measurement method (computer vs manual).
Results
We identiﬁed 448 articles. Seventy-nine (18%) articles met the
initial inclusion criteria and were read for further screening. Of
these,15 (19%) articles reported validity results and 11 (14%) articles
reported responsiveness results (Fig. 1).
Concurrent validity
Cross-sectional relationship between JSW and symptoms
Five studies evaluated the correlation between JSW and symp-
toms in the general population (Table I). In a population-based
study (3595 participants), the presence of hip pain, of moderate
and severe disability and, to a lesser extent, stiffness, were associ-
ated with minimal JSW3. In another population-based study (3208
participants), a minimal JSW 2 mm was signiﬁcantly associated
with self-reported pain in or around the hip joint during the
previous 12 months4. In 735 participants from the Johnston CountyTable I
Concurrent validity: correlations between symptoms and hip joint space metric measure
First author
(reference)
Design Number of
subjects/
patients
Mean age:
yrs (SD)
and % males
Type
Reijman3 Community-based
cohort, cross-sectional
3595 subjects
aged 55
years
66.0 6.9 years,
41.8%
Minim
with
3.0% w
1.4% w
Jacobsen4 Community-based,
cross-sectional
3208 Men: 62.5 (NA)
Women: 65.0
(NA), 37.8%
Minim
wome
 2.0
Gossec5 Subjects from a
community-based
cohort, cross-sectional
735 67.2 (9.5), 34.3% Categ
Birell6 Cross-sectional, patients
with new episode of hip
pain in primary care
195 Median age¼ 63,
33.3%
Dicho
cut of
Bierma-
Zienstra7
Descriptive,
cross-sectional
220 66 (9.6), 27% Dicho
2.5 m
Croft8 Cross-sectional, men who
underwent intravenous
urogram
759 Age between 60
and 75 years
Minim
OR: Odds Ratio.
95%CI: 95% Conﬁdential Interval.
mm: millimetre.Osteoarthritis Project, who had JSW measured at the ﬁrst follow-
up, categorized minimal JSWwas not related to pain, but a minimal
JSW< 2.5 mm was associated with functional impairment5. In
a sample of 195 patients presenting with new episodes of pain,
there was a negative correlation between JSW and duration of hip
pain6. In a sample of 220 patients consulting for hip pain, pain
duration 3 months was associated with a minimal
JSW 2.5 mm7. In 759 men aged 60e75 years, the prevalence of
hip pain was associated with a reduced minimal JSW8.
There were very few data on the relationship between JSW and
symptoms in hip OA patients (Table II). In a sample of 41 hip OA
patients, the functional impairment correlated with minimal and
sum JSW, in the operated and the contralateral hips9. Beside the
participants from the Johnston County Osteoarthritis Project, Ref. 5
also provided data from patients included in a 3-year RCT. The
baseline clinical parameters explained only 0.4% of the variability of
the baseline minimal JSW (P¼ 0.44).10 In the same sample, cate-
gorical JSW was not related to pain nor functional impairment5.
Longitudinal relationship between JSW and symptoms (Table II)
We did not ﬁnd any studies that evaluated the relationship
between change in symptoms and change in JSW. Two studies eval-
uated the relationship between baseline symptoms and subsequent
joint space loss. In 458 patients included in a 3-year RCT, baselinement (JSW) in the general population and in patients with hip pain
of JSW Results
al JSW 7.5% participants
minimal JSW 2.5 mm,
ith minimal JSW 2.0 mm,
ith minimal JSW 1.5 mm
Hip pain associated with minimal JSW 2.5 mm
(OR¼ 2.4, 95%CI¼ 1.7e3.4), 2.0 mm
(OR¼ 4.5, 95%CI¼ 2.9e7.0) and 1.5 mm
(OR¼ 6.6, 95%CI¼ 3.6e12.2)
Moderate disability associated with minimal
JSW 2.5 mm (OR¼ 2.7, 95%CI¼ 2.0e3.7),
2.0 mm (OR¼ 3.7, 95%CI¼ 2.4e5.9) and
1.5 mm (OR¼ 5.3, 95%CI¼ 2.9e9.8)
Severe disability associated with minimal
JSW 2.5 mm (OR¼ 3.0, 95%CI¼ 2.0e4.4),
2.0 mm (OR¼ 4.1, 95%CI¼ 2.5e7.0) and
1.5 mm (OR¼ 6.1, 95%CI¼ 3.1e12.1)
al JSW, 6.0% men and 5.7%
n with minimal JSW
mm
MJSW 2 mm signiﬁcantly associated to
self-reported hip pain (OR¼ 3.5, 95%CI¼ 2.1e5.7
in men; 1.7, 95%CI¼ 1.1e2.5 in females), groin
pain (OR¼ 2.3, 95%CI¼ 1.3e4.1 in men; 2.0,
95%CI¼ 1.3e3.2 in females), and thigh pain
(OR¼ 1.9, 95%CI¼ 1.1e3.3 in men; 1.5,
95%CI¼ 1.0e2.3 in females) during the previous
12 months
orical minimal JSW JSW not related to pain, JSW< 2.5 mm associated
with functional impairment, categorized in
quartiles (OR¼ 1.67, 95%CI¼ 1.0e2.78 compared
to JSW> 3 mm)
tomized minimal JSW,
f: 2.5 mm or 1.5 mm
Pain duration associated with JSW
Pain duration< 3 months, 28% with JSW 2.5
and 7% with JSW 1.5 mm; Pain duration¼ 3e12
months, 25% with JSW 2.5 and 13% with JSW
 1.5 mm; Pain duration> 12 months, 43% with
JSW 2.5 mm and 26% with JSW 1.5 mm,
P¼ 0.02
tomized minimal JSW,
m and 1.5 mm
JSW 2.5 mm correlated with pain duration
 3 months (OR¼ 2.34, 95%CI¼ 1.26e4.32) and
with morning stiffness (OR¼ 2.0, 95%
CI¼ 1.15e3.62)
JSW 1.5 mm correlated with morning stiffness
(OR¼ 2.6, 95%CI¼ 1.12e6.06)
al JSW Pain in 20.4% of hips, 28.3% of hips with JSW
 2.5 mm, and in 56% of hips with JSW 1.5 mm
Table II
Concurrent validity: cross-sectional and longitudinal correlations between symptoms and JSW metric measurement in hip OA patients
Reference Design Number of
patients
Age, years, mean
(SD) and % males
Type of JSW Results
Amaro9 Descriptive, cross-sectional
Hip OA patients prior to
joint replacement
41 68.4 (9.4), 41% JSW continuous: minimal and
sum (lateralþ superiorþ axial)
JSW
Lequesne’s index correlated with minimal JSW, r¼0.57,
P< 0.05 for operated hip and r¼0.70, P< 0.05 for
non-operated hip
Lequesne’s index correlated with sum JSW, r¼0.63,
P< 0.05 for operated hip and r¼0.71, P< 0.05 for
non-operated hip
Dougados10 RCT, cross-sectional and
1-year follow-up
458 63.0 (7.0), 40.4% JSW continuous: dichotomized
change in minimal JSW
(0.6 mm or not)
Baseline clinical parameters explained only 0.4% of the
variability of the baseline JSW (P¼ 0.44)
Baseline Lequesne’s index> 10 related to 12 months
changes in JSW 0.6 mm (OR¼ 2.66, 95%CI¼ 1.46e4.83,
P< 0.0001)
Gossec5 Same RCT as above,
cross-sectional
507 63.0 (7.0), 40.4% Categorical minimal JSW,
cut-offs of 1.5, 2.5, and
3.0 mm
JSW not related to pain or functional impairment
Lane11 Cohort of women with
fractures, aged over
65 years
8-year follow-up
745 71.8 (5.2), 0% Change in minimal JSW,
continuous and dichotomized
(> or 0.5 mm)
Mean decrease in JSW¼ 0.5 0.63 and 0.35 0.55 mm in
hips with and without baseline pain, respectively
(P¼ 0.034)
Decrease 0.5 mm: 53.7% and 30.7% of hips with and
without baseline pain, respectively OR¼ 1.9,
95%CI¼ 1.4e2.6, P< 0.001)
OR: Odds Ratio.
95%CI: 95% Conﬁdential Interval.
mm: millimetre.
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1-year change in minimal JSW 0.6 mm10. In a study of 745 women
aged over 65with radiographic hip OA (936 hips), the joint space loss
during follow-up was increased in subjects with baseline hip pain11.Predictive validity
Prediction of future joint space loss (Table III)
In a retrospective study of 69 patients with hip OA who had
undergone total hip replacement (THR), the mean of mean JSW at
entry was not related to subsequent annual joint space loss (mean
follow-up¼ 81.2 59.9 months)12. In 458 patients included in
a 3-year RCT, a baseline minimal JSW< 2.0 mm was an indepen-
dent predictor of 12 month radiological progression10.
Prediction of future joint space loss or future joint replacement
In a prospective cohort (mean follow-up¼ 6.6 0.5 years),
a baseline minimal JSW 2.5 mm was a predictor of a joint space
loss 1.0 mm or a THR on a multivariate analysis performed on all
included subjects, but was not on an analysis restricted to the 411
patients with hip pain at baseline13.
Prediction of total hip joint replacement (Table IV)
A relationship between baseline JSW and later hip replacement
was observed in ﬁve studies (two of them evaluating the sameTable III
Predictive validity: correlations between JSW metric measurement and future joint spac
Reference Design and follow-up Number of
patients
Age, yea
and % m
Conrozier12 Retrospective study from a case registry of
patients who had undergone THR for OA,
mean radiological follow-up of 81.2 59.9
months
61 patients,
69 hips
Men: 62
Women:
44.2%
Dougados10 3-year RCT 458 63 (7), 4
OR: Odds Ratio.
95%CI: 95% Conﬁdential Interval.
mm: millimetre.sample). In a population-based study, a minimal JSW 2.5 mmwas
associatedwith subsequent THR (mean follow-up¼ 6.6 0.5 years)3.
In a cohortof195patientswithanewepisodeofhippain, thebaseline
minimal JSW was predictive of being put on a waiting list for joint
replacement (median duration follow-up¼ 36months)14. In a cohort
of 224 subjects aged> 50 yearswith hip pain followed-up for amean
2.7 0.25 years then 5.8 0.3 years, a baseline joint space< 2.5 mm
was predictive of future joint replacement on unadjusted analysis15.
In 506 patients included in a 3-year RCT, a baseline minimal
JSW< 2 mm and the ﬁrst year change in minimal JSW were associ-
atedwith THRduring the 2-year follow-up16. Patients included in the
same RCT were followed-up for an additional 2 years. A decrease of
minimal JSW of at least 0.2 mm during the ﬁrst year predicted joint
replacement during the 4 following years and a decrease of minimal
JSW of at least 0.4 mm during the ﬁrst two years predicted joint
replacement during the 3 following years17.Responsiveness
Data on minimal JSW were extracted from 11 articles (seven
cohorts, four RCTs)11,12,18e26. Structural assessment analysis was
performed as an ITT analysis in three RCTs, and as a completer
analysis in the last RCT and in the cohorts. The assessment of
minimal JSW was performed using a manual technique in four
studies, and a computer-based technique in seven. The meane loss in hip OA patients
rs, mean (SD)
ales
Type of JSW Results
.0 (10.4)
61.8 (10.4),
JSW continuous:
mean JSW
The mean JSW at entry was not related
to further annual joint space loss
0.4% JSW continuous Baseline JSW< 2.0 mm was an independent
predictor of a further 0e1 year radiological
progression, deﬁned as a 1-year JSW loss
of at least 0.6 mm (OR¼ 2.11, 95%
CI¼ 1.30e3.44)
Table IV
Predictive validity: correlation between hip joint space metric measurement (JSW) and future THR
Reference Design and follow-up Number of
subjects/patients
Age, years, mean
(SD) and % males
Type of JSW Results
Reijman3 Community-based cohort,
mean follow-up¼ 6.6 0.5 years
3561 67.1 (7.98) Mean JSW Baseline JSW 2.5 mm predicts future THR
OR right hip¼ 18.6, 95%CI¼ 10.7e32.3
OR left hip¼ 22.6, 95%CI¼ 11.8e43.0
Birrell14 Cohort of patients with a new
episode of hip pain recruited by
GPs, median duration
follow-up¼ 36 months
195 63 (11), 32% Minimal JSW JSW predictive of future THR
In a 0e6 composite score for prediction
of THR, the weight of JSW is 2 (joint
space> 2.5¼ 0, JSW 1.5e2.5¼ 1,
joint space< 1.5¼ 2)
Lievense15 Patients aged >50 years with
hip pain, followed-up for a
mean 2.7 0.25 years then
5.8 0.3 years
193 (mean follow-up
2.7 years) and
163 subjects (mean
follow-up¼ 5.8 years)
65.6 (9.6), 26.9% Minimal JSW Baseline JSW< 2.5 mm predictor of future
THR on univariate (OR for future 3 years
THR¼ 6.6, P< 0.01; OR for future 6 years
THR¼ 7.1, P< 0.01), but not on multivariate
analysis
Dougados16 3-year RCT 506 Minimal JSW: 1-year
change in JSW
categorized in four
grades (no change,
worsening< 25%,
worsening between
25% and 50%,
worsening> 50%)
Baseline JSW< 2 mm associated with a
THR during the 3 following years (relative
risk¼ 1.85, 95%CI¼ 1.18e2.90)
First year change in JSW associated with
THR during the 2 following years, relative
risk of being operated¼ 2.89; P< 0.01
(grade 1 vs 2); 2.09, P¼ 0.07 (grade 2 vs 3);
and 5.3, P< 0.0001 (grade 3 vs 4)
Maillefert17 3-year RCTþ 2 years of
additional follow-up after
end of the trial
422 (ﬁrst analysis) and
384 (second analysis)
63.0 (6.8), 41.7%
(ﬁrst analysis)
and 43.7%
(second analysis)
Minimal JSW A 1-year decrease in JSW 0.2 mm or 15%
predicted THR during the next 4 years
(sensibility and speciﬁcity of 75% and 68%;
74% and 78%, respectively)
Similar results for 0e2 years changes in JSW
OR: Odds Ratio.
95%CI: 95% Conﬁdential Interval.
mm: millimetre.
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was 0.66 (95% conﬁdential interval (95%CI)¼ 0.41e0.91). The
responsiveness tended to be higher in cohorts (SRM¼ 0.83; 95%CI:
0.49, 1.16) than in RCTs (SRM¼ 0.35; 95%CI: 0.12, 0.57). Respon-
siveness was also higher in analyses of completers (SRM¼ 0.80;
95%CI: 0.50, 1.10) compared to ITT analyses (SRM¼ 0.30; 95%CI:
0.06, 0.55). Responsiveness varied by method of measurement,
with greater responsiveness seen in studies using computer-based
measurement (SRM¼ 1.12; 95%CI: 0.64, 1.59) compared to manual
measurement (SRM¼ 0.47; 95%CI: 0.31, 0.62).
The data on mean JSW and joint space area were too sparse to
allow any pooled analysis. Some studies suggested responsiveness
to be comparable to that observed for minimal JSW12,18,20,27.
Discussion
The present study focused on metric measurement of JSW
since it is currently the most frequently used method evaluating
structural changes on X-rays in clinical trials21,22,25,26 and hasTable V
Summary of hip responsiveness from radiographs using random-effects pooling of
the SRM of the minimum JSW
Analysis Number of
studies
Mean sample
size
SRM 95% Conﬁdence
Interval
Overall 11 164 0.66 0.41, 0.91
Study design
RCT 4 111 0.35 0.12, 0.57
Cohort 7 194 0.83 0.49, 1.16
Analysis
Completers 8 176 0.80 0.50, 1.10
ITT 3 132 0.30 0.06, 0.55
Measurement technique
Computer 4 40 1.12 0.64, 1.59
Manual 7 234 0.47 0.31, 0.62been demonstrated to be more responsive than other methods,
such as the Kellgren and Lawrence or the OARSI grading systems5.
The main limitation is the heterogeneity of the included studies in
their design, inclusion and exclusion criteria, sample size,
outcomes.
The results suggest that, in the general population as well as in
the subjects with hip pain, there is an association betweenminimal
JSW and the presence of hip symptoms. Surprisingly, the relation-
ship between JSW and symptoms has rarely been evaluated in hip
OA patients. In this review, the results of cross-sectional correla-
tions were too sparse and heterogeneous to allow any conclusion,
while longitudinal studies suggested that baseline joint symptoms
are moderately correlated to subsequent joint space loss.
Several factors must be taken into account when interpreting
these results. First, joint pain is inﬂuenced by numerous factors,
including patient-related factors. A recent study showed that the
relationship between pain and joint space (non-metric measure-
ment) is increased when the patients are their own controls, at
least for the knee28. It would be interesting to conduct such a study,
using JSW metric measurement, in hip OA patients. Second, OA is
symptomatically a disease with ﬂuctuating symptoms, which
makes it difﬁcult to interpret the correlations between structural
data and symptomatic data obtained at only one point in time.
Again, additional studies evaluating the relationship between JSW
and symptoms obtained at several points of time would be of
interest. Third, most studies did not adjust for analgesic and non-
steroidal anti-inﬂammatory drug consumption when evaluating
the association between JSW and symptoms. This might alter the
associations, at least with respect to pain.
Taken together, the results of this analysis suggest that there is
some evidence of a weak association between JSW and symptoms
in hip OA. However, additional studies are needed to clarify the
association.
Results on predictive validity suggest that absolute levels of JSW
might be predictive of later joint space loss, though these data are
D. Chu Miow Lin et al. / Osteoarthritis and Cartilage 19 (2011) 543e549548heterogeneous; there is more data to suggest that loss of JSW is
predictive of subsequent THR. One can question the relevance of
joint replacement as an end-point to evaluate the validity of JSW.
While arthroplasty is usually performed in patients with advanced
symptomatic and structural disease, surgeons have reported that
they are weakly or moderately inﬂuenced by X-rays when deciding
whether joint replacement is indicated or not29,30. It has also been
shown that in clinical practice, JSW is a major predictive factor of
the decision to perform hip replacement31. Thus, JSW and joint
replacement might not be truly independent. However, the reasons
why JSW inﬂuences the surgeons’ decision remain unclear. If these
reasons are differential diagnosis (some surgeons might consider
that pain and functional impairment are certainly due to OA in
patients with severe joint space narrowing, but might be due, at
least in part, to another disease in those with mild joint space
narrowing), optional treatments (the surgeons might consider that
an additional or complementary medical treatment is less likely to
be efﬁcient in patients with severe joint narrowing), and/or
disease’s potential evolution (surgeons might consider that
a spontaneous clinical improvement is less likely to be observed in
patients with severe joint loss), joint replacement might be
considered as a valid outcome.
The present results suggest good evidence for a moderate
responsiveness of JSW in hip OA. It must be pointed out however
that the responsiveness tended to be lower in RCTs than in cohort
studies, and lower using an ITT rather than a completer analysis
(which might explain the higher responsiveness in cohort studies).
Potential DMOADs are evaluated using RCTs and an ITT analysis, so
the responsiveness of JSW in such studies should be considered as
mild, rather than moderate.
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